Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VBI Vaccines : Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting

11/22/2019 | 08:52am EDT

'The clinical outcomes from Part A, the tumor responses we've seen in three of the six patients in the high-dose cohort in Part A, and now again the tumor response seen in one of the two patients enrolled and evaluable to-date in Part B continue to be encouraging,' said David E. Anderson, Ph.D., VBI's Chief Scientific Officer. 'In an effort to better understand these early tumor response data, we are also characterizing baseline biomarkers and immunologic responses, notably T cell responses. Correlations between immunological biomarkers and tumor/clinical responses will be refined as more patients are enrolled in Part B of the study.'

To-date, the ongoing Phase 1/2a open-label multicenter study has enrolled all 18 recurrent GBM patients in Part A of the study and four first-recurrent GBM patients in Part B. As of the cut-off date of November 18, 2019, of the four patients enrolled in Part B of the study, two were evaluable for immunologic responses, and one was evaluable for tumor response.

Disclaimer

VBI Vaccines Inc. published this content on 22 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 November 2019 13:51:03 UTC


© Publicnow 2019
All news about VBI VACCINES INC.
06/17VBI VACCINES  : to Present at Upcoming Scientific Conferences (Form 8-K)
PU
06/17VBI VACCINES INC/BC  : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
06/17VBI VACCINES  : to Present at Upcoming Scientific Conferences
BU
06/10VBI VACCINES  : Announces Results of Annual General Meeting (Form 8-K)
PU
06/10VBI VACCINES INC/BC  : Submission of Matters to a Vote of Security Holders, Othe..
AQ
06/09VBI VACCINES  : Announces Results of Annual General Meeting
BU
06/09VBI VACCINES  : Announces Multiple Abstracts Accepted for Poster Presentations a..
BU
06/09VBI VACCINES  : EASL 2021 (Form 8-K)
PU
06/08VBI VACCINES  : Wins FDA Fast Track Designation for Cancer Vaccine; Shares Rise
MT
06/08VBI VACCINES  : Granted FDA Fast Track Designation for VBI-1901 for the Treatmen..
BU
More news
Financials (USD)
Sales 2021 3,40 M - -
Net income 2021 -70,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -14,0x
Yield 2021 -
Capitalization 996 M 996 M -
Capi. / Sales 2021 293x
Capi. / Sales 2022 20,0x
Nbr of Employees 130
Free-Float 74,8%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 8,00 $
Last Close Price 3,92 $
Spread / Highest target 130%
Spread / Average Target 104%
Spread / Lowest Target 78,6%
EPS Revisions
Managers and Directors
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Christopher McNulty CFO, Director & Head-Business Development
Steven H. Gillis Chairman
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.42.55%996
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367